{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:41:24Z","timestamp":1790606484654,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The prognosis of cancer patients has greatly improved in the last years, owing to the development of novel chemotherapeutic agents. However, this progress comes with an increasing occurrence of cardiovascular adverse reactions. A serious side effect is arterial hypertension (HT), which is the most frequent comorbidity encountered in cancer patients, influencing the outcomes in cancer survivors. Even though secondary HT related to specific chemotherapeutic agents, such as vascular endothelial growth factor inhibitors, is usually mild and reversible, in rare instances it can be severe, leading to discontinuation of chemotherapy. In addition, HT per se has been studied as a potential risk factor for cancer development. The relationship is even more complex than previously thought, as concerning evidence recently highlighted the potential oncogenic effects of antihypertensive drugs, particularly thiazide diuretics, which may increase the risk of skin cancer. As a result, in light of the similar risk factors and overlapping pathophysiological mechanisms between HT and cancer, a promising concept of onco-hypertension has emerged, aiming to improve the understanding of the complicated interplay between these two pathologies and maintain a balance between the efficacy and risks of both antihypertensive drugs and chemotherapy agents.<\/jats:p>","DOI":"10.3390\/ijms25063442","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:36:31Z","timestamp":1710822991000},"page":"3442","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension"],"prefix":"10.3390","volume":"25","author":[{"given":"Stefan","family":"Totolici","sequence":"first","affiliation":[{"name":"Cardio-Thoracic Pathology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Cardiology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Vrabie","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic Pathology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Cardiology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-3054","authenticated-orcid":false,"given":"Elisabeta","family":"Badila","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic Pathology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Cardiology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Weiss","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic Pathology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients","volume":"128","author":"Dobbin","year":"2021","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/23993693211001374","article-title":"Onco-hypertension: Overview of hypertension with anti-cancer agents","volume":"5","author":"Ruf","year":"2021","journal-title":"J. Onco-Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1055-9965.EPI-17-0510","article-title":"Blood pressure status in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study","volume":"26","author":"Gibson","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Connaughton, M., and Dabagh, M. (2022). Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis. Healthcare, 10.","DOI":"10.3390\/healthcare10061074"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"379252","DOI":"10.1155\/2013\/379252","article-title":"Incidence of new-onset hypertension in cancer patients: A retrospective cohort study","volume":"2013","author":"Fraeman","year":"2013","journal-title":"Int. J. Hypertens."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer Therapy-Related Hypertension: A Scientific Statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"ref_8","first-page":"165","article-title":"The Relationship between Hypertension and Cancer","volume":"24","author":"Rapoport","year":"2022","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11897-023-00590-5","article-title":"Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies","volume":"20","author":"Tini","year":"2023","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40959-021-00101-2","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"TMohammed","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e390876","DOI":"10.1200\/EDBK_390876","article-title":"Managing Adverse Effects Associated with Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","article-title":"Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors","volume":"128","author":"Fleming","year":"2021","journal-title":"Circ. Res."},{"key":"ref_18","unstructured":"(2024, January 22). Cardiovascular Adverse Effects of Novel Bruton Tyrosine Kinase Inhibitors: What All Cardiologists Should Know\u2014American College of Cardiology. [Online]. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/08\/15\/16\/45\/CV-Adverse-Effects-of-Novel-Bruton-Tyrosine-Kinase-Inhibitors."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tam, C.S., Opat, S., D\u2019Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R.G., Marlton, P., Wahlin, B.E., and Sanz, R.G. (2024, January 12). A Randomized Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: The ASPEN Study. [Online]. Available online: http:\/\/ashpublications.org\/blood\/article-pdf\/136\/18\/2038\/1779238\/bloodbld2020006844.pdf.","DOI":"10.1182\/blood.2020006844"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib Versus Ibrutinib in Relapsed\/ Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial","volume":"41","author":"Hillmen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FJC.0000000000001342","article-title":"Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment","volume":"80","author":"Chuquin","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.medici.2016.03.002","article-title":"Hypertension, serum lipids and cancer risk: A review of epidemiological evidence","volume":"52","author":"Kuzmickiene","year":"2016","journal-title":"Medicina"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/aje\/kwm321","article-title":"Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition","volume":"167","author":"Weikert","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/HYPERTENSIONAHA.120.14820","article-title":"Association of Hypertension and Blood Pressure with Kidney Cancer Risk: A Nationwide Population-Based Cohort Study","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/CEJ.0000000000000578","article-title":"The association between hypertension and colorectal cancer: A meta-analysis of observational studies","volume":"30","author":"Xuan","year":"2021","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44877","DOI":"10.1038\/srep44877","article-title":"Hypertension and breast cancer risk: A systematic review and meta-analysis","volume":"7","author":"Han","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31358","DOI":"10.1038\/srep31358","article-title":"Hypertension and risk of prostate cancer: A systematic review and meta-analysis","volume":"6","author":"Liang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_29","first-page":"113","article-title":"The association between hypertension and prostate cancer","volume":"19","author":"Navin","year":"2017","journal-title":"Rev. Urol."},{"key":"ref_30","unstructured":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"SCORE2-OP Working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J., 42, 2455\u20132467.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: Understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","article-title":"Toxicity of cancer therapy: What the cardiologist needs to know about angiogenesis inhibitors","volume":"104","author":"Dobbin","year":"2018","journal-title":"Heart"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for themanagement of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC CardioOncology"},{"key":"ref_36","unstructured":"Gottlieb, S. (2024, January 15). FDA Statement on the FDA\u2019s Ongoing Investigation into Valsartan and ARB Class Impurities and the Agency\u2019s Steps to Address the Root Causes of the Safety Issues, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10552-005-0349-8","article-title":"A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States)","volume":"16","author":"Flaherty","year":"2005","journal-title":"Cancer Causes Control"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910630212","article-title":"International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension","volume":"63","author":"McLaughlin","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14740\/jocmr3744","article-title":"Association Between the Use of Thiazide Diuretics and the Risk of Skin Cancers: A Meta-Analysis of Observational Studies","volume":"11","author":"Shin","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdin.2023.04.007","article-title":"Hydrochlorothiazide increases risk of nonmelanoma skin cancer in an elderly Japanese cohort with hypertension: The Shizuoka study","volume":"12","author":"Hashizume","year":"2023","journal-title":"JAAD Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamainternmed.2018.1652","article-title":"Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma","volume":"178","author":"Pedersen","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nochaiwong, S., Chuamanochan, M., Ruengorn, C., Noppakun, K., Awiphan, R., Phosuya, C., Tovanabutra, N., Chiewchanvit, S., Sood, M.M., and Hutton, B. (2022). Use of Thiazide Diuretics and Risk of All Types of Skin Cancers: An Updated Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14102566"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shao, S.C., Lai, C.C., Chen, Y.H., Lai, E.C.C., Hung, M.J., and Chi, C.C. (2022). Associations of thiazide use with skin cancers: A systematic review and meta-analysis. BMC Med., 20.","DOI":"10.1186\/s12916-022-02419-9"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1096\/fj.03-0129com","article-title":"Differential regulation of in vivo angiogenesis by angiotensin II receptors","volume":"17","author":"Walther","year":"2003","journal-title":"FASEB J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/ajrccm.159.2.9804132","article-title":"Airway Neural Responses to Kinins Tachyphylaxis and Role of Receptor Subtypes","volume":"159","author":"Reynolds","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","article-title":"Involvement of substance P and the NK-1 receptor in human pathology","volume":"46","year":"2014","journal-title":"Amino Acids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"736361","DOI":"10.3389\/fendo.2021.736361","article-title":"The Effect of Local Renin Angiotensin System in the Common Types of Cancer","volume":"12","author":"Almutlaq","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","article-title":"Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk","volume":"108","author":"Sipahi","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","article-title":"Antihypertensive treatment and risk of cancer: An individual participant data meta-analysis","volume":"22","author":"Copland","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sipahi, I. (2022). Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263461"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"ARB Trialists Collaboration (2011). Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J. Hypertens., 29, 623\u2013635.","DOI":"10.1097\/HJH.0b013e328344a7de"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/EDE.0000000000000483","article-title":"Use of calcium channel blockers and risk of breast cancer: A population-based cohort study","volume":"27","author":"Azoulay","year":"2016","journal-title":"Epidemiology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women","volume":"18","author":"Wilson","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41440-023-01382-z","article-title":"Use of calcium channel blockers and risk of breast cancer among women aged 55 years and older: A nationwide population-based cohort study","volume":"46","author":"Minegishi","year":"2023","journal-title":"Hypertens. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3442\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:15:45Z","timestamp":1760105745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063442"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063442","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}